Australia Pharmaceutical Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 13.21 Billion |
| Market Size (2029) | USD 17.89 Billion |
| CAGR (2024 - 2029) | 6.25 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Australia Pharmaceutical Market Analysis
The Australia Pharmaceuticals Market size is estimated at USD 13.21 billion in 2024, and is expected to reach USD 17.89 billion by 2029, growing at a CAGR of 6.25% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market studied in Australia. Many companies received approval for their vaccines against the Sars-CoV-2 virus and focused their research and development on therapeutics against COVID-19. For instance, in January 2021, the Therapeutic Goods Administration approved the COVID-19 vaccine developed by Pfizer and BioNTech. In addition, the Australian government signed nearly four agreements and invested around AUD 3.3 billion to support the supply of vaccines in the country. Furthermore, the country invested around AUD 363 million in research and development activities related to the prevention and treatment of COVID-19. Such developments accelerated market growth during a pandemic. Furthermore, the Australian Government has convened a large group of clinical experts to form the National COVID-19 Clinical Evidence Taskforce. The role of the taskforce is to create evidence-based Australian guidelines for the clinical care of people with COVID-19. The Therapeutic Goods Administration (TGA) approved Tixa Genmab and ciljevima (Evoshield) in December 2021 and Sotrovimab (Xevudy) in August 2021 for COVID-19 treatment. Hence, it is observed that the COVID-19 pandemic had a significant impact on the market studied.
The major factors likely to drive market growth during the forecast period are the growing burden of chronic diseases and the rising geriatric population, along with the rising investments in research and development expenditure for novel therapeutics in Australia. According to Australian Bureau of Statistics data updated in March 2022, over three-quarters, i.e., 78.6% of Australians, had at least one long-term health condition in 2021, while nearly half, 46.6% or 11.6 million, had at least one chronic condition. Thus, increasing chronic diseases and a high demand for pharmaceutical products are expected to promote market growth. Furthermore, the burden of diabetes has also increased in the country. As per the data in the International Diabetes Federation's 2021 report, there were about 1.5 million people with diabetes in Australia in 2021, and their number is expected to increase to 1.9 million by 2045. Thus, the demand for pharmaceuticals for diabetes treatment and management is expected to increase over the years in Australia, which is expected to boost growth in the pharmaceuticals market in the country.
Additionally, key strategies adopted by major market players, increased investment, and rising research and development activities will also contribute to market growth. For instance, in June 2022, diabetes-focused biotech player Dimerix entered into a partnership agreement with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to conduct a clinical trial of its oral medical product DMX-200 in diabetic kidney disease patients. Positive results from such studies will boost their demand, hence boosting the pharmaceutical manufacturing process and thereby driving the market during the study period. Thus, the above-mentioned factors are expected to positively contribute to the market's growth over the study period.
However, strict regulatory guidelines for product approvals are expected to hinder market growth.
Australia Pharmaceutical Market Trends
The Prescription Drugs Segment Holds the Largest Share and is Expected to do so in the Forecast Period
Prescription drugs are available with a valid prescription from a prescriber. These drugs are heavily regulated and require a visit to a doctor, a diagnosis, and monitoring by a doctor to ensure the medication is working and that it is working safely.
According to the November 2021 report of the Australian Institute of Health and Welfare (AIHW), about 16% of the total Australian population was of age 65 years and more, and the older population is on the rise. The rising geriatric population is expected to fuel the market growth as they are more prone to various chronic diseases such as cancer, cardiovascular diseases, musculoskeletal diseases, and others. The increasing burden of chronic diseases is one of the key factors fueling the demand for therapeutic drugs which will boost the market. In addition, the launch of new drugs in the country requiring a doctor's prescription is expected to positively contribute to the segment's growth. For instance, in January 2022, Australia's drug regulator approved two prescription drugs for the treatment of COVID-19, Lagevrio by Merck and Paxlovid from Pfizer.
Moreover, technological advancements in the segment with the purpose to ease the prescription process will also drive the market. For instance, in February 2022, the Australian Capital Territory Government launched Canberra Script, a real-time prescription monitoring system to enable medical professionals to assess patients' drug history before prescribing and dispensing some medications. It is being implemented to help address the increasing harms caused by some prescription medications, particularly opioids.
Therefore, due to the aforementioned factors, the prescription drugs segment is expected to have a significant market share in the pharmaceutical market in Australia over the forecast period.
Generic Drugs are Expected to Witness Strong Growth in Coming Years
A generic drug is a medication created to be the same as an already marketed branded drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.
The use of generic drugs in Australia is continuously rising due to their cost-effectiveness and the presence of pharmaceutical companies that develop such generic medicines. Additionally, the key steps taken by the Australian government play a crucial role in the demand for generic medicine. For instance, in March 2022, the Indian and Australian governments signed an agreement through which Indian pharmaceutical companies will get easy access to the Australian market for launching their products. The Therapeutic Good Administration (TGA) of Australia agreed to expedite faster and easier approval for the drug developed by Indian pharmaceutical companies. With such agreements, the segment is expected to witness strong growth in the coming years.
Furthermore, new launches of generic drugs in Australia are accelerating segment growth. For instance, in March 2022, TiefenbacherPharmaceuticals successfully launched the first generic version of the Epilepsy medicine Lacosamide in Australia. Lacosamide is used for the treatment of seizures in patients suffering from epilepsy. The tablets are being marketed in Australia in the strengths 50mg, 100mg, 150mg, and 200mg. With the launch of such drugs for crucial diseases, the genetic drug demand is expected to witness a significant hike in the coming years across the country.
Australia Pharmaceutical Industry Overview
The Australian pharmaceutical market is highly competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the key companies currently dominating the market are Abbvie Inc., Amgen Inc., Pfizer Inc., AstraZeneca, and Eli Lilly and Company.
Australia Pharmaceutical Market Leaders
-
Abbvie Inc.
-
Amgen Inc.
-
AstraZeneca plc
-
Eli Lilly & Co.
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Australia Pharmaceutical Market News
- Jun, 2022: Tetra Bio-Pharma launched its new wholly owned subsidiary 'Tetra Bio-Pharma Australia' (TBP-AU), an Australian-based research company focused on the execution of clinical trials in Australia.
- Mar, 2022: Antengene Corporation Limited announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO (selinexor) for the treatment of adult patients with multiple myeloma (MM).
Australia Pharmaceutical Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Geriatric Population and Increasing Investments in the Sector
- 4.2.2 Rising Incidence of Chronic Diseases such as CVD and Diabetes
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Scenario
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products and/ or Services
- 4.4.5 Degree of Competition/Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By ATC/Therapeutic Class
- 5.1.1 Alimentary Tract and Metabolism
- 5.1.2 Blood and Blood Forming Organs
- 5.1.3 Cardiovascular System
- 5.1.4 Dermatologicals
- 5.1.5 Genito Urinary System and Sex Hormones
- 5.1.6 Systemic Hormonal Preparations
- 5.1.7 Anti-infectives for Systemic Use
- 5.1.8 Antineoplastic and Immunomodulating Agents
- 5.1.9 Musculoskeletal System
- 5.1.10 Nervous System
- 5.1.11 Antiparasitic Products, Insecticides, and Repellents
- 5.1.12 Respiratory System
- 5.1.13 Sensory Organs
- 5.1.14 Other Therapeutic Classes
-
5.2 By Drug Type
- 5.2.1 Branded
- 5.2.2 Generic
-
5.3 By Prescription Type
- 5.3.1 Prescription Drugs (Rx)
- 5.3.2 OTC Drugs
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 AstraZeneca PLC
- 6.1.3 Amgen Inc.
- 6.1.4 Pfizer Inc.
- 6.1.5 CSL Limited
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 GlaxoSmithKline PLC
- 6.1.8 Eli Lilly and Company
- 6.1.9 Novartis AG
- 6.1.10 Sanofi SA
- 6.1.11 Johnson and Johnson
- 6.1.12 Merck KGaA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Australia Pharmaceutical Industry Segmentation
As per the scope of this report, pharmaceuticals are referred to as prescription and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The Australia Pharmaceuticals Market is segmented by ATC/Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals, Genito Urinary System and Sex Hormones, Systemic Hormonal Preparations, Anti-infectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Antiparasitic Products, Insecticides, and Repellents, Respiratory System, Sensory Organs, and Other Therapeutic Classes), Drug Type (Branded and Generic), and Prescription Type (Prescription Drugs (Rx) and OTC Drugs). The report offers the value (in USD million) for the above segments.
| By ATC/Therapeutic Class | Alimentary Tract and Metabolism |
| Blood and Blood Forming Organs | |
| Cardiovascular System | |
| Dermatologicals | |
| Genito Urinary System and Sex Hormones | |
| Systemic Hormonal Preparations | |
| Anti-infectives for Systemic Use | |
| Antineoplastic and Immunomodulating Agents | |
| Musculoskeletal System | |
| Nervous System | |
| Antiparasitic Products, Insecticides, and Repellents | |
| Respiratory System | |
| Sensory Organs | |
| Other Therapeutic Classes | |
| By Drug Type | Branded |
| Generic | |
| By Prescription Type | Prescription Drugs (Rx) |
| OTC Drugs |
Australia Pharmaceutical Market Research FAQs
How big is the Australia Pharmaceuticals Market?
The Australia Pharmaceuticals Market size is expected to reach USD 13.21 billion in 2024 and grow at a CAGR of 6.25% to reach USD 17.89 billion by 2029.
What is the current Australia Pharmaceuticals Market size?
In 2024, the Australia Pharmaceuticals Market size is expected to reach USD 13.21 billion.
Who are the key players in Australia Pharmaceuticals Market?
Abbvie Inc., Amgen Inc., AstraZeneca plc, Eli Lilly & Co. and Pfizer Inc. are the major companies operating in the Australia Pharmaceuticals Market.
What years does this Australia Pharmaceuticals Market cover, and what was the market size in 2023?
In 2023, the Australia Pharmaceuticals Market size was estimated at USD 12.38 billion. The report covers the Australia Pharmaceuticals Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Australia Pharmaceuticals Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the challenges for foreign pharma companies entering the Australian Market?
The challenges for foreign pharma companies entering the Australian Market are a) Competition b) Regulatory hurdles c) Potential need for local partnerships
What are the challenges for foreign pharma companies entering the Australian Market?
The challenges for foreign pharma companies entering the Australian Market are a) Competition b) Regulatory hurdles c) Potential need for local partnerships
Australia Pharmaceutical Industry Report
The pharmaceutical industry in Australia is poised for sustained growth, propelled by an aging population and the increasing prevalence of chronic diseases like diabetes, which are boosting demand for ongoing treatment management. The market is primarily dominated by the prescription drugs segment, benefiting from substantial investments in research and development for innovative therapeutics. Additionally, there is a notable surge in the adoption of generic drugs, spurred by government initiatives and their cost-effectiveness. Technological advancements in medical technology and the introduction of efficient drug monitoring systems are also enhancing prescription safety and further fueling market expansion. Strategic partnerships and an emphasis on expanding drug portfolios are expected to continue driving the positive trajectory of the pharmaceutical industry in Australia. For a detailed market forecast and analysis, refer to the latest industry reports which offer insights into market share, size, and revenue growth trends. Access a free report PDF download for an in-depth industry analysis.
